Literature DB >> 22292617

Drugs and mitochondrial diseases: 40 queries and answers.

Michelangelo Mancuso1, Daniele Orsucci, Massimiliano Filosto, Costanza Simoncini, Gabriele Siciliano.   

Abstract

INTRODUCTION: Mitochondrial disorders are a group of metabolic conditions caused by impairment of the oxidative phosphorylation system. The treatment of mitochondrial diseases is still inadequate. Therapies that have been attempted include: respiratory chain cofactors, other metabolites secondarily decreased in mitochondrial disorders, antioxidants, and agents acting on lactic acidosis. However, their role in the treatment of the majority of mitochondrial diseases is still unclear. Furthermore, some drugs may potentially have detrimental effects on mitochondrial dysfunction. AREAS COVERED: To critically review this still unclear field, this paper attempts to answer, on the basis of the basic and clinical literature available to date, the 'frequently asked questions', such as: Is valproic acid safe in mitochondrial patients? What about other antiepileptic drugs? May metformin trigger lactic acidosis in mitochondrial patients? Are statins safe in these subjects? EXPERT OPINION: Randomized clinical trials are necessary to establish efficacy and safety of drugs. Multicenter collaboration is essential for the advancement of therapy for mitochondrial disorders.

Entities:  

Mesh:

Year:  2012        PMID: 22292617     DOI: 10.1517/14656566.2012.657177

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  12 in total

Review 1.  Drug development for rare mitochondrial disorders.

Authors:  Orest Hurko
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 2.  Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.

Authors:  Antonello Di Paolo; Elena Arrigoni
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

3.  Treatment of mitochondrial disorders.

Authors:  Sreenivas Avula; Sumit Parikh; Scott Demarest; Jonathan Kurz; Andrea Gropman
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

4.  Comparative Analysis of Experimental Methods to Quantify Animal Activity in Caenorhabditis elegans Models of Mitochondrial Disease.

Authors:  Manuela Lavorato; Neal D Mathew; Nina Shah; Eiko Nakamaru-Ogiso; Marni J Falk
Journal:  J Vis Exp       Date:  2021-04-04       Impact factor: 1.355

Review 5.  Current and Emerging Clinical Treatment in Mitochondrial Disease.

Authors:  Rory J Tinker; Albert Z Lim; Renae J Stefanetti; Robert McFarland
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

6.  Revealing the Complexity of Mitochondrial DNA-Related Disorders.

Authors:  Daniele Orsucci; Gabriele Siciliano; Michelangelo Mancuso
Journal:  EBioMedicine       Date:  2018-03-09       Impact factor: 8.143

Review 7.  Mitochondrial disorders and drugs: what every physician should know.

Authors:  Daniele Orsucci; Elena Caldarazzo Ienco; Gabriele Siciliano; Michelangelo Mancuso
Journal:  Drugs Context       Date:  2019-07-04

Review 8.  Genetics of ischaemic stroke in young adults.

Authors:  Eva Terni; Nicola Giannini; Marco Brondi; Vincenzo Montano; Ubaldo Bonuccelli; Michelangelo Mancuso
Journal:  BBA Clin       Date:  2014-12-29

Review 9.  Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson's Disease.

Authors:  Mesfer Al Shahrani; Simon Heales; Iain Hargreaves; Michael Orford
Journal:  J Clin Med       Date:  2017-10-27       Impact factor: 4.241

Review 10.  Anesthetic management of a pediatric patient with Electron Transfer Flavoprotein Dehydrogenase deficiency (ETFDH) and acute appendicitis: case report and review of the literature.

Authors:  Emmanuel Lilitsis; Elisavet Astyrakaki; Evaggelos Blevrakis; Sofia Xenaki; George Chalkiadakis; Emmanuel Chrysos
Journal:  BMC Anesthesiol       Date:  2017-08-29       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.